The total return over the past 12 months is +106.29% vs. +16.94% for the S&P 500. So far it's up +129.97% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +106.29% | +16.06% | N/A | N/A | N/A | N/A |
| Total Return CAGR | +106.29% | +16.06% | N/A | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Amylyx Pharmaceuticals, Inc. (AMLX)
| Year | Start price | End price | AMLX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $12.08 | $27.78 | +129.97% | +14.51% | +115.46% |
| 2025 | $3.78 | $12.08 | +219.58% | +17.72% | +201.86% |
| 2024 | $14.72 | $3.78 | (74.32%) | +24.89% | (99.21%) |
| 2023 | $36.95 | $14.72 | (60.16%) | +26.19% | (86.35%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
